ATE406899T1 - Neutrale endopeptidase (nep) und humane lösliche endopeptidase (hsep) hemmer für die prophylaxe und behandlung von neurodegenerativen erkrankungen - Google Patents

Neutrale endopeptidase (nep) und humane lösliche endopeptidase (hsep) hemmer für die prophylaxe und behandlung von neurodegenerativen erkrankungen

Info

Publication number
ATE406899T1
ATE406899T1 AT05701469T AT05701469T ATE406899T1 AT E406899 T1 ATE406899 T1 AT E406899T1 AT 05701469 T AT05701469 T AT 05701469T AT 05701469 T AT05701469 T AT 05701469T AT E406899 T1 ATE406899 T1 AT E406899T1
Authority
AT
Austria
Prior art keywords
endopeptidase
hsep
nep
prophylaxis
treatment
Prior art date
Application number
AT05701469T
Other languages
English (en)
Inventor
Michael Weske
Lechoslaw A Turski
Hrissanthi Ikonomidou
Dieter Ziegler
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34796705&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE406899(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Application granted granted Critical
Publication of ATE406899T1 publication Critical patent/ATE406899T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT05701469T 2004-01-12 2005-01-10 Neutrale endopeptidase (nep) und humane lösliche endopeptidase (hsep) hemmer für die prophylaxe und behandlung von neurodegenerativen erkrankungen ATE406899T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53553804P 2004-01-12 2004-01-12
EP04100067 2004-01-12

Publications (1)

Publication Number Publication Date
ATE406899T1 true ATE406899T1 (de) 2008-09-15

Family

ID=34796705

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05701469T ATE406899T1 (de) 2004-01-12 2005-01-10 Neutrale endopeptidase (nep) und humane lösliche endopeptidase (hsep) hemmer für die prophylaxe und behandlung von neurodegenerativen erkrankungen

Country Status (22)

Country Link
EP (1) EP1706121B1 (de)
JP (1) JP4951350B2 (de)
KR (1) KR101219580B1 (de)
CN (1) CN101076339B (de)
AT (1) ATE406899T1 (de)
AU (1) AU2005205067B2 (de)
BR (1) BRPI0506750A (de)
CA (1) CA2551789C (de)
CY (1) CY1108588T1 (de)
DE (1) DE602005009487D1 (de)
DK (1) DK1706121T3 (de)
ES (1) ES2313279T3 (de)
HR (1) HRP20080611T3 (de)
IL (1) IL176456A (de)
NO (1) NO20063623L (de)
PL (1) PL1706121T3 (de)
PT (1) PT1706121E (de)
RU (1) RU2362563C2 (de)
SI (1) SI1706121T1 (de)
UA (1) UA82008C2 (de)
WO (1) WO2005067937A1 (de)
ZA (1) ZA200605549B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2389182A1 (de) * 2009-01-24 2011-11-30 Phytopharm PLC Behandlung von erkrankungen, die durch den neurotrophen faktor vermittelt werden
AR079059A1 (es) 2009-12-07 2011-12-21 Abbott Healthcare Products Bv Acido ((3s)-3-(((1-(((2r)-2-carboxi-4-(1-naftil) butil) ciclopentil)-carbonil) amino )-2-oxo-2,3,4,5-tetrahidro-1h-1-benzazepin-1-il) acetico cristalino, su preparacion y uso
CN106065006B (zh) * 2015-04-22 2020-06-05 深圳信立泰药业股份有限公司 一种中性内肽酶抑制剂盐晶型及其制备方法
PL424453A1 (pl) * 2018-01-31 2019-08-12 Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością Sposoby zmniejszania szkodliwego działania niedoboru perfuzji narządów miąższowych przez inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP)
PL424452A1 (pl) 2018-01-31 2019-08-12 Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu
CN110590695B (zh) * 2019-10-22 2023-03-21 南华大学 苯并氮杂环类化合物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19510566A1 (de) * 1995-03-23 1996-09-26 Kali Chemie Pharma Gmbh Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19750002A1 (de) * 1997-11-12 1999-05-20 Solvay Pharm Gmbh Phosphonsäure-substituierte Benzazepinon-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
HUP0101640A3 (en) * 1998-04-23 2002-10-28 Novartis Ag Certain thoil inhibitors of endothelin-converting enzyme
US20020013307A1 (en) * 2000-05-23 2002-01-31 Pablo Lapuerta Use of vasopeptidase inhibitors to treat or slow the progression of cognitive dysfunction and to treat and/or prevent dementia
US6505135B2 (en) * 2001-03-13 2003-01-07 Micro Motion, Inc. Initialization algorithm for drive control in a coriolis flowmeter
CZ20033183A3 (cs) * 2001-05-18 2004-07-14 Solvay Pharmaceuticals Gmbh Použití sloučenin s kombinovanou inhibiční aktivitou NEP/ MP v přípravě léčiv
CL2004000545A1 (es) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul

Also Published As

Publication number Publication date
CY1108588T1 (el) 2014-04-09
NO20063623L (no) 2006-10-12
PT1706121E (pt) 2008-12-04
HRP20080611T3 (en) 2008-12-31
RU2362563C2 (ru) 2009-07-27
DE602005009487D1 (de) 2008-10-16
AU2005205067A1 (en) 2005-07-28
UA82008C2 (uk) 2008-02-25
JP2007517834A (ja) 2007-07-05
AU2005205067B2 (en) 2009-10-22
JP4951350B2 (ja) 2012-06-13
CN101076339A (zh) 2007-11-21
EP1706121A1 (de) 2006-10-04
PL1706121T3 (pl) 2009-02-27
IL176456A (en) 2010-03-28
RU2006129288A (ru) 2008-02-20
ES2313279T3 (es) 2009-03-01
IL176456A0 (en) 2006-10-05
KR20060123541A (ko) 2006-12-01
ZA200605549B (en) 2007-12-27
WO2005067937A1 (de) 2005-07-28
EP1706121B1 (de) 2008-09-03
DK1706121T3 (da) 2009-01-05
KR101219580B1 (ko) 2013-01-08
CA2551789A1 (en) 2005-07-28
CN101076339B (zh) 2011-02-09
SI1706121T1 (sl) 2009-02-28
BRPI0506750A (pt) 2007-05-22
CA2551789C (en) 2011-05-03

Similar Documents

Publication Publication Date Title
MX2012001985A (es) Derivados de 3-amino-5-fenil-5,6-dihidro-2h-[1,4]oxazina.
NO20060324L (no) [1,8]Naftyridin-2-oner og relaterte forbindelser for behandling av Schizofreni
GEP20125565B (en) Lactam compounds and their pharmaceutical use
NO20074592L (no) Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister
IL176546A0 (en) Imidazoline derivatives having cb1-antagonistic activity
ZA200600579B (en) Piperazine derivatives and methods of use
MA27305A1 (fr) Derives de 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene et leur utilisation en tant qu'inhibiteurs de renine dans le traitement de l'hypertension, de maladies cardiovasculaires ou renales
TW200604196A (en) New quinuclidine derivatives and pharmaceutical compositions comprising them
ATE406899T1 (de) Neutrale endopeptidase (nep) und humane lösliche endopeptidase (hsep) hemmer für die prophylaxe und behandlung von neurodegenerativen erkrankungen
CR9622A (es) Derivados de pirazolo[3,4-d]azepina como antagonistas de histamina h3
TW200602297A (en) Sulfonamide compounds for the treatment of neurodegenerative disorders
WO2005097114A3 (en) Thiazole sulfonamide compounds for the treatment of neurodegenerative disorders
ATE402150T1 (de) Pyrazolaminverbindungen zur behandlung neurodegenerativer erkrankungen
WO2007034326A3 (en) Imidazole compounds for the treatment of neurological disorders
ATE453638T1 (de) Amidinderivate von 2-heteroarylchinazolinen und chinolinen; wirksame analgetika und entzündungshemmende mittel
WO2005095361A8 (en) Isoxazole- and isothiazole-amine compounds for the treatment of neurodegenerative disorders
ATE355287T1 (de) 2-oxo-1,3,4-trihydrochinazolin derivative zur behandlung von zellproliferationskrankheiten
TH126304A (th) สารยับยั้งของนิวตราลเอนโดเพปติเดส (Neutral Endopeptidase) (NEP) และของเอนโดเพปติเดส (Endopeptidase) ที่ละลายของคน (hSEP) สำหรับป้องกันและรักษาความผิดปกติที่เป็นการเสื่อมสลายของประสาท
UA84737C2 (ru) Производные имидазолина с антагонистической активностью относительно cb1
TW200621255A (en) Novel compounds

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1706121

Country of ref document: EP